BG60933B2 - Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него - Google Patents

Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него Download PDF

Info

Publication number
BG60933B2
BG60933B2 BG98632A BG9863294A BG60933B2 BG 60933 B2 BG60933 B2 BG 60933B2 BG 98632 A BG98632 A BG 98632A BG 9863294 A BG9863294 A BG 9863294A BG 60933 B2 BG60933 B2 BG 60933B2
Authority
BG
Bulgaria
Prior art keywords
clmf
protein
sir
leu
cells
Prior art date
Application number
BG98632A
Other languages
Bulgarian (bg)
English (en)
Inventor
Richard Chizzonite
Maurice Gately
Ulrich Gubler
Jeffrey Hulmes
Yu-Ching Pan
Frank Podlaski
Alvin Stern
Original Assignee
F. Hoffmann- La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27412641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG60933(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann- La Roche Ag filed Critical F. Hoffmann- La Roche Ag
Publication of BG60933B2 publication Critical patent/BG60933B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG98632A 1989-12-22 1994-03-01 Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него BG60933B2 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45570889A 1989-12-22 1989-12-22
US52093590A 1990-05-09 1990-05-09
US57228490A 1990-08-27 1990-08-27

Publications (1)

Publication Number Publication Date
BG60933B2 true BG60933B2 (bg) 1996-06-28

Family

ID=27412641

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98632A BG60933B2 (bg) 1989-12-22 1994-03-01 Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него

Country Status (11)

Country Link
EP (4) EP0790255B1 (fr)
JP (2) JP3238418B2 (fr)
AT (4) ATE366311T1 (fr)
AU (2) AU6834990A (fr)
BG (1) BG60933B2 (fr)
CA (3) CA2572802A1 (fr)
DE (4) DE69032086T2 (fr)
DK (4) DK0790255T3 (fr)
HU (1) HU211879A9 (fr)
IE (1) IE904694A1 (fr)
NZ (1) NZ236545A (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
EP0375045A1 (fr) * 1988-12-22 1990-06-27 Duphar International Research B.V Dérivés d'indoles annelés
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
EP0772689B1 (fr) 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Vecteurs retroviraux a taux de recombinaison reduit
WO1996024369A1 (fr) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations de preparation d'interleukine-12
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
AU702379B2 (en) * 1996-06-04 1999-02-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Novel feline cytokine protein
CA2268365A1 (fr) * 1996-10-18 1998-04-30 Jeff Nordstrom Expression du gene il-12, systemes d'apport et utilisations
JP2001503258A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド 遺伝子発現および搬送系および用途
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998041229A1 (fr) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag Utilisation du il-12p40 comme immunostimulant
JP2002241398A (ja) * 1997-06-03 2002-08-28 Chemo Sero Therapeut Res Inst 新規なイヌサイトカインタンパク質
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
AU2005202420B2 (en) * 1999-09-09 2008-08-07 Merck Sharp & Dohme Corp. Mammalian cytokines; related reagents and methods
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP1905832A3 (fr) * 1999-09-09 2009-09-09 Schering Corporation Interleukin-12 P40 et interleukin B30 de mammifères, anticorps, utilisation dans des compositions pharmaceutiques
ATE389019T1 (de) * 1999-09-09 2008-03-15 Schering Corp Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
PL206701B1 (pl) 2001-03-07 2010-09-30 Merck Patent Gmbh Immunoglobulinowe białko fuzyjne, kodujący je kwas nukleinowy, replikujący wektor ekspresji zawierający taki kwas nukleinowy, eukariotyczna komórka gospodarza zawierająca taki wektor ekspresji oraz sposób zwiększania ekspresji takiego białka fuzyjnego
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
MXPA05006384A (es) 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
EA016022B1 (ru) 2004-12-21 2012-01-30 Сентокор, Инк. Выделенное антитело млекопитающего против il-12 и способ изменения его активности
EP1966238B1 (fr) 2005-12-30 2012-04-25 Merck Patent GmbH Variants de polypeptides p40 de l'interleukine 12 ayant une stabilité améliorée
BRPI0819656A2 (pt) 2007-11-27 2015-06-23 Ablynx Nv Seqüências de aminoácidos contras citocinas heterodiméricas e/ou seus receptores e polipeptídeos compreendendo as mesmas
US7891807B2 (en) * 2009-06-11 2011-02-22 Ana Nichole Mansuy Decorative eyeglass temples
AU2017241776A1 (en) 2016-03-29 2018-10-11 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
US10189151B2 (en) 2016-11-14 2019-01-29 Snap-On Incorporated Compact head body hammer
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
FI3883606T3 (fi) 2018-09-24 2023-09-07 Janssen Biotech Inc Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2893653B2 (ja) * 1988-11-10 1999-05-24 ジェネティックス・インスティテュート・インコーポレイテッド ナチュラルキラー細胞刺激因子
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor

Also Published As

Publication number Publication date
EP0433827A3 (en) 1992-07-01
DE69034249D1 (de) 2007-09-20
DK0790308T3 (da) 2007-10-08
EP0790309B1 (fr) 2007-07-25
CA2346997A1 (fr) 1991-06-23
EP0790255A3 (fr) 2000-03-01
IE990007A1 (en) 2000-11-01
JP3238418B2 (ja) 2001-12-17
JPH05294999A (ja) 1993-11-09
DE69034247T2 (de) 2008-04-17
DE69034244D1 (de) 2007-08-16
IE990005A1 (en) 2000-11-01
IE990006A1 (en) 2000-11-01
AU674363B2 (en) 1996-12-19
HU211879A9 (en) 1995-12-28
ATE369383T1 (de) 2007-08-15
DK0433827T3 (da) 1998-09-28
CA2572802A1 (fr) 1991-06-23
AU5471294A (en) 1994-06-09
JP2002167400A (ja) 2002-06-11
CA2032653A1 (fr) 1991-06-23
CA2346997C (fr) 2007-02-20
AU6834990A (en) 1991-06-27
CA2032653C (fr) 2002-05-28
DE69032086T2 (de) 1998-09-17
DE69034249T2 (de) 2008-05-29
JP3375949B2 (ja) 2003-02-10
IE904694A1 (en) 1991-07-17
DK0790309T3 (da) 2007-11-05
ATE368112T1 (de) 2007-08-15
EP0433827A2 (fr) 1991-06-26
ATE163675T1 (de) 1998-03-15
DE69032086D1 (de) 1998-04-09
DE69034247D1 (de) 2007-09-06
EP0790309A1 (fr) 1997-08-20
DK0790255T3 (da) 2007-11-26
EP0790255B1 (fr) 2007-08-08
NZ236545A (en) 1993-04-28
EP0790308B1 (fr) 2007-07-04
EP0433827B1 (fr) 1998-03-04
EP0790255A2 (fr) 1997-08-20
EP0790308A1 (fr) 1997-08-20
DE69034244T2 (de) 2008-04-03
ATE366311T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
BG60933B2 (bg) Цитотоксичен лимфоцитен фактор на съзряване и многоклонални антитела срещу него
US5780597A (en) Monoclonal antibodies to cytotoxic lymphocyte maturation factor
Williams et al. Identification of a ligand for the c-kit proto-oncogene
JP2541761B2 (ja) ミュレル管抑制物質様ポリペプチドおよびその製造方法
NL8900178A (nl) Groei regulerende clycoproteinen.
NZ332921A (en) Method of treating cellular degeneration using neurturin and related growth factors
WO1992000376A1 (fr) Facteur de croissance de mastocytes
US8133873B2 (en) Recombinant chemokine-antigen vaccine
CA2128151A1 (fr) Recepteurs de l'interleukine 12 et anticorps
JPH06189787A (ja) モノクローナル抗体、ハイブリドーマおよびそれらの用途
WO1993007271A1 (fr) Facteur de stimulation d'une colonie d'osteoclastes (o-csf)
EP1467752A1 (fr) Proteines membranaires de mastocytes exprimees
IE19990005A1 (en) Monoclonal antibodies directed to the cytotoxic lymphocyte maturation factor
IE85054B1 (en) Monoclonal antibodies directed to the cytotoxic lymphocyte maturation factor
IE19990006A1 (en) Cytotoxic lymphocyte maturation factor 40kD subunit and monoclonal antibodies directed thereto
IE85055B1 (en) Cytotoxic lymphocyte maturation factor 40kD subunit and monoclonal antibodies directed thereto
IE19990007A1 (en) Cytotoxic Lymphocyte Maturation Factor